title: Polyelectrolyte capsules as carriers for growth factor inhibitor delivery to hepatocellular carcinoma.
abstract: The efficient internalization of TGF-beta inhibitor-loaded polyelectrolyte capsules and particles is studied in two HCC cell lines. Two polyelectrolyte pairs (biocompatible but not degradable and biodegradable crosslinked with gluteraldehyde) are employed for coating. The capsules are characterized by SEM. LY is successfully loaded inside the core and embedded between polymer layers. MS is used to quantify the loading efficiency by comparing post-loading and core-loading methods, since both coated templates and hollow shells are used as carriers. CLSM confirms dissolution of the pre-formed multilayer upon enzymatic degradation as the method of release, and migration assays demonstrate a higher inhibition efficiency of TGF-beta in tailored biodegradable capsules compared to free LY administration.
authors.affiliation: Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari, Medical School, Bari, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Baldassarre
authors.forename: Viviana
authors.initials: V
authors.lastname: Vergaro
authors.forename: Flavia
authors.initials: F
authors.lastname: Scarlino
authors.forename: Flavia
authors.initials: F
authors.lastname: De Santis
authors.forename: Giovanna
authors.initials: G
authors.lastname: Lucarelli
authors.forename: Antonio Della
authors.initials: AD
authors.lastname: Torre
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ciccarella
authors.forename: Ross
authors.initials: R
authors.lastname: Rinaldi
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Giannelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Leporatti
mesh_terms: D001672:Biocompatible Materials / Q000138:chemical synthesis* / Q000494:pharmacology; D002214:Capsules / Q000138:chemical synthesis* / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003432:Cross-Linking Reagents / Q000737:chemistry; D004337:Drug Carriers / Q000138:chemical synthesis* / Q000494:pharmacology; D004339:Drug Compounding; D004705:Endocytosis / Q000187:drug effects; D005976:Glutaral / Q000737:chemistry; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D011073:Polyamines / Q000138:chemical synthesis* / Q000494:pharmacology; D000071228:Polyelectrolytes; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology*; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000037:antagonists & inhibitors*
chemical_list: D001672:Biocompatible Materials; D002214:Capsules; D003432:Cross-Linking Reagents; D004337:Drug Carriers; D005976:Glutaral; D011073:Polyamines; D000071228:Polyelectrolytes; D017346:Protein Serine-Threonine Kinases; D011720:Pyrazoles; D011758:Pyrroles; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta; C530108:LY2109761